Journal of
eISSN: 2376-0060
Submit manuscript...
Editorial Volume 9 Issue 3
Whole inactivated COVID-19 vaccines: effect on adult symptomatic-COVID-19 infection
Attapon Cheepsattayakorn,1,2 
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Ruangrong Cheepsattayakorn,3 Porntep Siriwanarangsun1
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
1Faculty of Medicine, Western University, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology, Chiang Mai University, Thailand
Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand
Received: September 10, 2022 | Published: September 14, 2022
Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. Whole inactivated COVID-19 vaccines: effect on adult symptomatic-COVID-19 infection. J Lung Pulm Respir Res. 2022;9(3):61. DOI: 10.15406/jlprr.2022.09.00281
Editorial
Recently, a large phase-III-clinical trial on persons with age of 18 years or above, conducted by Bharat Biotech International Limited, “ COVAXIN® ” (BBV152), a whole vision inactivated corona virus vaccine demonstrated that two doses of its vaccine with an interval of 4 weeks of administration had 78 % of efficacy against any COVID-19 (live SARS-CoV-2) severity and 93 % of efficacy against severe COVID-19 after 14 days or more after the second dose administration.1 Whereas vaccine efficacy was 79 % in adults with age of 60 years or below, and 68 % in those with age of 60 years or above.1 On the median of follow-up of 99 days, the vaccine efficacy in persons with asymptomatic COVID-19 infection was 64 %.1 A recent study on effect of two whole inactivated COVID-19 vaccines (two intramuscular injections, 21 days apart) among adults with symptomatic COVID-19 infection revealed that COVID-19 vaccine with 5 µg/dose (n = 13,459) and vaccine with 4 µg/dose (n = 13,465) had the vaccine efficacy of 72.8 % and 78.1 %, respectively, compared with control group (n = 13,458) of 95 % (77 days of median duration), whereas the adverse reactions at 7 days after each injection were around 41.7 % to 46.5 % of the study participants.2
In conclusion, these two whole inactivated COVID-19 vaccines could decrease the risk of symptomatic COVID-19 infection among adults, whereas the use of COVAXIN® in adults with age of 18 years or above.
Acknowledgments
None.
Conflicts of interest
There are no conflicting interests declared by the authors.
References
- World Health Organization. COVID-19 Vaccine Explainer. COVID-19 vaccine (Whole virion inactivated coronavirus vaccine), BBV152, COVAXIN®. 2022.
- Kaabi NA, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.
©2022 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.
Citations
November is Lung Cancer Awareness Month, a vital opportunity for us to raise awareness about the dangers of lung cancer. Let’s unite to educate ourselves and others, and inspire proactive steps toward lung health. This year the motto of this event is “Stronger Together: United for Lung Cancer Awareness”. So for this occasion, the Journal of Lung, Pulmonary & Respiratory Research invites articles that emphasize the significance of lung protection. All the submissions received in the month of November will be offered with 40% discount on publication.